Laikangqita Monoclonal Antibody
Psoriasis
NDAMarketing application accepted and granted priority review
Key Facts
Indication
Psoriasis
Phase
NDA
Status
Marketing application accepted and granted priority review
Company
About Livzon Pharmaceutical
A major integrated Chinese pharmaceutical group with strong R&D in microsphere technology, biologics, and traditional Chinese medicine.
View full company profileTherapeutic Areas
Other Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| Autoimmune psoriasis candidate | Nyrada | Preclinical |
| CYPS317 | FibroBiologics | Discovery |
| PEP Biologic™ | Intent Biologics | Unknown |
| DMT410 | Dermata Therapeutics | Preclinical |
| IL23R program | Acellera | Pre-clinical |
| Undisclosed Psoriasis Program | Nepsone | Preclinical |
| TEM-1657 (Topical) | Temisis | Pre-clinical |
| TEM-1657 (Oral) | Temisis | Pre-clinical |
| AIM Platform | Phaim Pharma | Pre-clinical |
| orismilast | UNION therapeutics | Phase 2 |
| CT-P55 | Celltrion | Phase 3 |
| JNJ-77242113 | Johnson & Johnson | Phase 3 |